RxDoctor Payments Data

Fnu Saba Mushtaq, MD

Family Medicine · Dallas, TXNPI 1295221232

Payments from drug & device makers

$4,358in general payments, 2019–2025

Across 247 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$739
  • Lilly USA, LLC$510
  • AstraZeneca$466
  • Novo Nordisk$441
  • GSK$397
  • Pfizer$222
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,358 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$3,467
Medicare patients
24
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$64,131
JardianceEmpagliflozin41$52,807
EliquisApixaban56$51,792
FarxigaDapagliflozin Propanediol48$40,243
MounjaroTirzepatide25$25,934
RybelsusSemaglutide13$23,873
XareltoRivaroxaban36$23,634
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,474
JanuviaSitagliptin Phosphate13$19,748
Repatha SureclickEvolocumab31$17,074
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$6,468
SymbicortBudesonide/Formoterol Fumarate25$6,355
Tresiba Flextouch U-100Insulin Degludec21$5,897
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$4,742
Atorvastatin Calcium521$3,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$441$88,00570 claims
Boehringer IngelheimJardiance$145$52,80741 claims
PfizerEliquis$222$51,79256 claims
AstraZenecaFarxiga, Symbicort$466$46,59873 claims
Lilly USA, LLCMounjaro$510$25,93425 claims
Johnson & JohnsonXarelto$67$23,63436 claims
GSKTrelegy Ellipta$397$21,47432 claims
MerckJanuvia$53$19,74813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →